Bell Potter analyst Sam Brandwood maintained a Buy rating on IPD Group Ltd (IPG – Research Report) today and set a price target of A$5.50. The ...

MA Financial Group analyst Matthew Chen CFA maintained a Buy rating on IPD Group Ltd (IPG – Research Report) on February 24 and set a price ...

Wh Analytics, a leading provider of Climate Insurance for renewable energy assets, revealed today a new visual identity and a re-designed website that reflect the company's evolution and expanding ...

IPD Group Ltd ( ($AU:IPG) ) just unveiled an update. IPD Group Limited reported record half-year revenues and earnings for the period ending ...

IPD Group Ltd ( ($AU:IPG) ) has shared an announcement. IPD Group Ltd has released its FY25 half-year results, detailing financial performance and ...

Like Queen Elizabeth, she loves horses and a great tiara moment. Meghan Markle's refreshed lifestyle brand has a logo with a meaningful symbol. On Feb. 18, the Duchess of Sussex announced that she ...

Just like the brand’s logo, the brand’s name is full of meaning, too. In an Instagram video, Meghan explained, “As Ever essentially means ‘as it’s always been,’ and if you’ve ...

Five years later, we can tell the tale of using the tools of science, we were able to turn the tide on SARS-CoV-2 and, in the process, rewrite the playbook on pandemic preparedness. Through ...

The Green Party's new logo is an emoji. The federal party unveiled its new brand, a green dot, on Tuesday on Parliament Hill, possibly weeks before a snap federal election. "The great thing about ...

What is the current share price of IPD Group Ltd (IPG)? IPD Group Ltd's (IPG) current share price is $4.10. This constitutes a price movement of 2.84% when compared to the share price 7 days ago and ...

Meghan Markle's refreshed lifestyle brand has a logo with a meaningful symbol. On Feb. 18, the Duchess of Sussex announced that she was rebranding her lifestyle venture previously known as ...

Gene therapies can be life-changing for people, but the high cost plus the burden of treatment remain barriers to access and utilization, explained Kevin Niehoff, PharmD, BCMAS, of IPD Analytics.